CROI 2014

Oral dual therapy effective for HCV genotype 1b

Oral dual therapy effective for HCV genotype 1b

LEAGUE-1 study findings on a dual oral hepatitis C virus therapy consisting of daclatasvir and simeprevir, without interferon or ribavirin, are encouraging.

Interferon-free regimen effective in HCV, HIV coinfection

Interferon-free regimen effective in HCV, HIV coinfection

By

Rates of sustained virologic response ranged from 70% to 90% among patients with HCV and HIV coinfection in the PHOTON-1 study.

Novel triple-drug HCV combo achieves high SVR

Novel triple-drug HCV combo achieves high SVR

By

Direct-acting investigational "three-D" combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.

Once-daily tx promising in HCV, HIV coinfection

Once-daily tx promising in HCV, HIV coinfection

By

Simeprevir plus pegylated interferon and ribavirin promising in previously untreated patients with hepatitis C and HIV coinfection.

Shorter HCV treatment strategy yields benefits

Shorter HCV treatment strategy yields benefits

By

A six-week combination regimen appeared to be as effective as 12 weeks of therapy for patients with hepatitis C virus infections.

Sign Up for Free e-newsletters